Etomoxir, a carnitine palmitoyltransferase-1 inhibitor, has also been demonstrated to limit spheroid formation in breast cancer in vitro and reduce tumor growth in vivo by blocking fatty acid oxidation [93, 135,136,137]
250 Preliminary human studies, particularly in elderly populations, have reached early-stage clinical investigation, suggesting potential for clinical translation
The maintenance frequency approach represents hybrid strategy where initial intensive treatment (daily application for 3-6 months) establishes improvements, then reduces to maintenance schedule (2-3 times weekly or every other day) rather than complete discontinuation
M., Manger, P., Nienhuis, R., Fahringer, H